Literature DB >> 23288882

Granulation pattern, but not GSP or GHR mutation, is associated with clinical characteristics in somatostatin-naive patients with somatotroph adenomas.

Sarah Larkin1, Raghava Reddy, Niki Karavitaki, Simon Cudlip, John Wass, Olaf Ansorge.   

Abstract

OBJECTIVE: Somatotroph adenomas causing acromegaly are histologically classified into densely granulated (DG) and sparsely granulated (SG) subtypes with different morphology, clinical characteristics and treatment outcomes. Granulation pattern has been reported to co-segregate with a recurrent mutation at codon 49 in growth hormone receptor (GHR) and GSP oncogene. This study examines response to the octreotide suppression test (OST) in relation to granulation pattern and mutation in GHR and GSP.
DESIGN: This is a retrospective, single-centre study of 52 patients with pathologically confirmed somatotroph adenoma who were naïve to medical therapy presenting between January 2001 and October 2010.
METHODS: Clinical, radiological and hormonal data at diagnosis were recorded. GHR and GSP were genotyped, granulation pattern determined and response to the OST measured.
RESULTS: SG adenomas were larger (P=0.038), occurred in younger patients (P=0.029), were more common in females (P=0.026) and were more invasive (P<0.0001 and P=0.001), with diminished responses to the OST (P=0.007) compared with DG adenomas. GSP mutation was unrelated to granulation pattern but associated with smaller tumours (P=0.027), producing more GH (P=0.048) that responded better to the OST (P=0.022). Codon 49 of GHR was not mutated.
CONCLUSIONS: Adenoma histological phenotype, not genotype, corresponds to clinical and biochemical characteristics and response to the OST. SG adenomas constitute a clinically more unfavourable subtype but are not associated with GHR mutations in our series. Ascertainment of the adenoma subtype may become an important consideration in the management of acromegaly.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23288882     DOI: 10.1530/EJE-12-0864

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  35 in total

Review 1.  Somatostatin receptor ligands in acromegaly: clinical response and factors predicting resistance.

Authors:  Rosa Maria Paragliola; Salvatore Maria Corsello; Roberto Salvatori
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

Review 2.  International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature.

Authors:  Thomas Günther; Giovanni Tulipano; Pascal Dournaud; Corinne Bousquet; Zsolt Csaba; Hans-Jürgen Kreienkamp; Amelie Lupp; Márta Korbonits; Justo P Castaño; Hans-Jürgen Wester; Michael Culler; Shlomo Melmed; Stefan Schulz
Journal:  Pharmacol Rev       Date:  2018-10       Impact factor: 25.468

3.  A structural and functional acromegaly classification.

Authors:  Daniel Cuevas-Ramos; John D Carmichael; Odelia Cooper; Vivien S Bonert; Arkadiusz Gertych; Adam N Mamelak; Shlomo Melmed
Journal:  J Clin Endocrinol Metab       Date:  2015-01       Impact factor: 5.958

4.  Growth hormone tumor histological subtypes predict response to surgical and medical therapy.

Authors:  Katja Kiseljak-Vassiliades; Nichole E Carlson; Manuel T Borges; B K Kleinschmidt-DeMasters; Kevin O Lillehei; Janice M Kerr; Margaret E Wierman
Journal:  Endocrine       Date:  2014-08-17       Impact factor: 3.633

5.  Expression of cell cycle regulators and biomarkers of proliferation and regrowth in human pituitary adenomas.

Authors:  Mark Gruppetta; Robert Formosa; Sharon Falzon; Sabrina Ariff Scicluna; Edward Falzon; James Degeatano; Josanne Vassallo
Journal:  Pituitary       Date:  2017-06       Impact factor: 4.107

6.  Clinical, biological, radiological, and pathological comparison of sparsely and densely granulated somatotroph adenomas: a single center experience from a cohort of 131 patients with acromegaly.

Authors:  Amy A Swanson; Dana Erickson; Diane Mary Donegan; Sarah M Jenkins; Jamie J Van Gompel; John L D Atkinson; Bradley J Erickson; Caterina Giannini
Journal:  Pituitary       Date:  2020-10-19       Impact factor: 4.107

Review 7.  Genomics and Epigenomics of Pituitary Tumors: What Do Pathologists Need to Know?

Authors:  Sylvia L Asa; Ozgur Mete; Shereen Ezzat
Journal:  Endocr Pathol       Date:  2021-01-12       Impact factor: 3.943

8.  Stereotactic radiosurgery for acromegaly: outcomes by adenoma subtype.

Authors:  Cheng-Chia Lee; Mary Lee Vance; M Beatriz Lopes; Zhiyuan Xu; Ching-Jen Chen; Jason Sheehan
Journal:  Pituitary       Date:  2015-06       Impact factor: 4.107

9.  Pros and cons in endocrine practice: pre-surgical treatment with somatostatin analogues in acromegaly.

Authors:  Marco Losa; Jens Bollerslev
Journal:  Endocrine       Date:  2016-01-19       Impact factor: 3.633

10.  Quantitative proteomics revealed the molecular characteristics of distinct types of granulated somatotroph adenomas.

Authors:  Yifan Tang; Tao Xie; Silin Wu; Qiaoqiao Yang; Tengfei Liu; Chen Li; Shuang Liu; Zhiyong Shao; Xiaobiao Zhang
Journal:  Endocrine       Date:  2021-05-27       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.